Whether ErbB2 receptor tyrosine kinase contributes to cervical cancer is controversial. We have examined the effects of E6 and E7 genes of human papillomaviruses type 16 (HPV-16) on ErbB2 expression in primary human cervical keratinocytes (HCK) immortalized with hTERT (HCK1T). In E6-positive cells (HCK1T-E6 and HCK1T-E6E7), ErbB2 expression levels increased with the cell density. HCK1T-E6E7 showed impaired contact inhibition and anchorage-independent growth in soft agar which were abrogated with introduction of ErbB2-specific short hairpin RNA (shRNA) or an ErbB2 specific inhibitor AG825. Furthermore, increased ErbB2 expression was also observed in HPV16 positive cervical cancer cell lines and this was diminished by introduction of HPV16E6-or E6AP-shRNA. At post-confluence cell densities, ErbB2 protein was stabilized in the presence of E6 whereas increased ErbB2 expression was not obvious with E6 mutants incapable of degrading p53. Furthermore, introduction of p53-shRNA to HCK1T resulted in increased ErbB2 protein stability, indicating possible ErbB2 regulation through p53. Finally, we showed that tumor formation of ErbB2-shRNA introduced SiHa cells were almost abolished. Taken together, these data indicate an important role of ErbB2 regulation by HPV16 E6 in oncogenic transformation of human cervical keratinocytes.
Introduction
Human papillomaviruses (HPVs) are believed to be the primary causal agents for development of preneoplastic and malignant lesions of the uterine cervix (Walboomers et al., 1999) , and high-risk types such as type 16 and 18 are associated with more than 90% of all cervical carcinomas (Walboomers et al., 1999) . The E6 and E7 genes of HPVs are thought to play causative roles, as E6 promotes the degradation of p53 through its interaction with E6AP, an E3 ubiquitin ligase, whereas E7 binds to the retinoblastoma protein Rb and disrupts its complex formation with E2F transcription factors (zur Hausen, 2002) . However, epidemiological studies and experimental data indicate that the viral presence is not enough to induce cervical cancer and additional cellular factors are presumably required (zur Hausen, 2002) .
ErbB2 (c-ErbB2, Her-2/neu), a proto-oncogene encoding a transmembrane receptor protein with an intracellular tyrosine kinase domain (Yamamoto et al., 1986; Hynes and Lane, 2005) , is a member of the ErbB/ epidermal growth factor (EGF) receptor family along with EGFR/ErbB1, ErbB3 and ErbB4 (Roskoski, 2004; Hynes and Lane, 2005) . In breast cancers, ErbB2 overexpression occurs in about 20 to 30% of cases with a poor prognosis and an anti-ErbB2 monoclonal antibody, trastuzumab (Herceptin), has been found effective for treatment (Roskoski, 2004; Hynes and Lane, 2005) . In cervical carcinomas, the reported incidence of antiErbB2 reactivity is highly variable, ranging from 20 to 100% (Ngan et al., 2001; Bellone et al., 2003) and gene amplification has been detected in 0 to 36% cases (Sharma et al., 1999; Rosty et al., 2004) . Thus, the significance of ErbB2 for cervical carcinogenesis is unclear. Furthermore, as some clinical reports have indicated a correlation between overexpression/amplification with a poor prognosis (Kihana et al., 1994; Nakano et al., 1997) , others have revealed no prognostic significance for cervical cancers (Ndubisi et al., 1997; Kersemaekers et al., 1999) .
Here, we report findings with normal human cervical keratinocytes (HCK), the dominant hosts for HPV16 infection and cells of origin of cervical cancers. To establish an in vitro model system for HPV16-mediated multistep carcinogenesis, normal HCK were immortalized by introduction of the human catalytic subunit of telomerase reverse transcriptase (hTERT). With these HCK1T cells, we found that HPV16 oncoproteins, E6 and E7, could induce anchorage-independent growth. Furthermore, we could show that E6 induces upregulation of ErbB2 receptor protein levels, which in turn play indispensable roles in HPV16 E6E7-mediated transformation.
Results
Establishment of a cervical carcinogenesis model with HPV16 E6 and E7 using immortalized primary HCK Normal HCK with an extended lifespan were isolated by introduction of hTERT, to provide a line, which we term HCK1T. To establish the in vitro model system for HPV16-mediated multistep carcinogenesis, these cells were infected with retroviral vectors expressing HPV16 E6 and E7 (HCK1T-E6E7), E6 alone (HCK1T-E6), E7 alone (HCK1T-E7), or control vector (HCK1T-vect). Functional expressions of these genes have been confirmed previously (Kiyono et al., 1998; Kyo et al., 2003) . Decreased p53 expression levels in E6-infected cells indicated functional expression of the E6 protein ( Figure 1a ) and expression of E7 was reconfirmed by Western blotting. Examination of the growth properties of these cells revealed exponential growth to be promoted in HCK1T-E6, KCK1T-E7 and HCK1T-E6E7 cells to similar extents as compared with HCK1T-vect cells (Figure 1b and Supplementary Figure 3) . Although growth of HCK1T-vect and HCK1T-E7 was abrogated on reaching confluence, HCK1T-E6E7 and HCK1T-E6 also showed significant increase in postconfluent (pc) cell densities (Figure 1c , Po0.005, n ¼ 3 compared with HCK1T-vect). The morphologies of HCK1T-vect and HCK1T-E6 cells at around confluence and postconfluence were in Supplementary  Figure 3 . HCK1T-E6E7 was furthermore found to be able to form colonies (8.871.4%) in soft agar with keratinocyte serum-free medium (KSFM) whereas HCK1T-E6 and HCK1T-E7 formed smaller colonies with much lower efficiencies (HCK1T-E6: 0.9170.1%, HCK1T-E7: 0.570.4%). HCK1T was unable to grow in soft agar (Figure 1d ). In conventional soft agar medium containing high calcium and 10% fetal bovine serum (FBS), none formed colonies. To determine the contribution of hTERT, a different strain of primary HCK was immortalized with or without hTERT. HCK12-E6E7 formed colonies (2.970.13%, not shown), but those immortalized with hTERT alone did not. Because human dermal keratinocyte (HDK) continued proliferating more than 40 population doublings (PDs), the anchorage-independent growth ability of HDK1-vect and HDK1-E6E7 was assessed. HDK1-E6E7 formed colonies (4.471.4%, not shown), but not HDK1-vect. These data suggest that p53 inactivation plus degradation of other E6 targeted proteins may confer the ability to overcome contact inhibition, but that inactivation of the Rb pathway by E7 alone is not sufficient. To gain anchorage-independent growth potential, both E6 and E7 are required.
Upregulation of ErbB2 expression induced by HPV16 E6 in HCK1T and dermal keratinocytes at postconfluent cell densities Taking advantage of our system using normal HCK, we addressed whether the ErbB2 receptor contributes to cervical carcinogenesis. First, we determined whether expression of ErbB2 was affected by E6 and/ or E7. Irrespective of the introduced genes, ErbB2 levels were unchanged when cells were exponentially growing (Figure 1a, sc) . However, remarkable upregulation of ErbB2 was observed in E6-positive cells (HCK1T-E6E7 and HCK1T-E6) at postconfluent cell densities (Figure 1a , left, pc). ErbB1 expression levels paralleled those for ErbB2 with smaller ranges in HCK1Ts (Supplementary Figure 1) . Among the downstream signaling molecules examined, the Akt pathway appeared to be a likely candidate involved in E6E7 induced transformation, because phosphorylation of Akt and 4-EBP1 was higher in E6-and/or E7-positive cells (Supplementary Figure 1) although further analysis is required for confirmation. Focusing on E6-dependent upregulation of ErbB2, this was observed also with HDK (HDK1-E6, Figure 1a , right, pc) and HPV16 positive cervical cancer cell lines as described below.
Dependency on ErbB2 for transformation of HCK1T-E6E7
The finding that E6 can induce ErbB2 upregulation led us to examine whether the transformed phenotype of HCK1T-E6E7 is dependent on this upregulation. An ErbB2 specific inhibitor AG825 with appropriate concentrations of 25 mM for normal human keratinocytes (Kansra et al., 2004) had only marginal effects on exponential growth of HCK1T cells, irrespective of the transduced genes (data not shown). Then the effects of 10 and 20 mM AG825 on growth beyond confluence were tested. Although the confluent cell density of HCK1T-vect was only partially suppressed, that of HCK1T-E6E7 cells was greatly suppressed with reduction of 76% with 20 mM AG825 (Figure 2a) . Furthermore, anchorage-independent growth of HCK1T-E6E7 cells was completely abolished (Figure 2b ), indicating that HPV16 E6-mediated ErbB2 upregulation may play a role in transformation of HCK and acquisition of the potential for unregulated growth, overcoming contact inhibition and becoming anchorage-independent.
To confirm this conclusion more directly, ErbB2 expression in HCK1T-E6E7 cells was suppressed with ErbB2-specific short hairpin RNA (shRNA). Stable expression of the shRNA reduced ErbB2 but not ErbB1 (data not shown) in both exponential-phase and postconfluent cells at levels comparable to those in HCK1T-vect cells (Figure 3a ). Exponential growth was not reduced (Figure 3b ), but postconfluent growth of HCK1T-E6E7 was significantly affected (Figure 3c ) and anchorage-independent growth was abolished by ErbB2 reduction (Figure 3d ). Therefore, with ErbB2-shRNA, there was no intrinsic defect in the exponential growth but rather a repression of growth advantage imparted by 16E6 that was notable in postconfluent, in soft agar and in the tumor in nude mice ( Figure 7 ). Furthermore, HCK1T-E7-ErbB2 (vs HCK1T-E7-E6) and HCK1T-E6E7-ErbB2 (vs HCK1T-E6E7-vect) showed superior colony forming ability (Supplementary Figure 2) confirming an important contribution of ErbB2 to HCK1Ts transformation. 
Increased ErbB2 protein stability in HPV16 E6-positive cells
To determine whether the increased ErbB2 expression by E6 in postconfluent cervical keratinocytes was owing to increased mRNA, ErbB2 mRNA was analysed by Northern blotting. The ErbB2 mRNA level in postconfluent SiHa cells was not elevated compared with exponentially growing cells. There was also no significant difference between postconfluent HCK1T-vect and HCK1T-E6 cells (Figure 5a ). Therefore, we concluded that ErbB2 protein is upregulated at the post-transcriptional level. Then we investigated the half-lives of ErbB2 protein in subconfluent and postconfluent SiHa cells. Cells were treated with cycloheximide (CHX) for the indicated time period and the ErbB2 degradation rate was monitored by Western blotting. The ErbB2 protein in postconfluent SiHa cells was more stable than that in subconfluent cells (Figure 5b , Po0.05 at 24 h). ErbB2 protein stability in postconfluent HCK1T-vect and HCK1T-E6 cells was also analysed and found to be greater in HCK1T-E6 than in HCK1T-vect cells (Figure 5d , Po0.05 at 6 and 9 h). Treatment of cells with the proteasome/lysosome inhibitor MG-132 prevented degradation of ErbB2 in HCK1T-vect cells whereas accumulation of ErbB2 was not obvious in HCK1T-E6 cells (Figure 5d ), suggesting that the degradation pathway inhibited by MG-132 is activated in postconfluent HCK1T-vect but not in HCK1T-E6. These data indicate that in postconfluent keratinocytes, HPV16 E6 suppresses degradation of ErbB2 leading to its increased stability and accumulation. After selection with puromycin, cell lysates were processed as for (a). Representative data from one of at least three experiments are presented. Gewin et al., 2004) therefore losing most of its functions (Gewin et al., 2004; Kelley et al., 2005) . E6D151 is a C-terminus deleted mutant incapable of binding to PDZ domain-containing proteins. E6 mutants unable to decrease p53 (E6SAT and E6L50G) could not stabilize ErbB2 in postconfluent cells (Figure 6a ). Then we directly examined whether p53 silencing by shRNA can stabilize ErbB2 protein in postconfluent HCK1T cells. ErbB2 stability in postconfluent HCK1T-p53-shRNA cells was increased (Figure 6b , n ¼ 3, Po0.05 at 9 h after CHX addition as compared to HCK1T-vect cells, n ¼ 3, Po0.05). These data indicate that E6-induced increase in ErbB2 protein is partly dependent on E6-mediated p53 degradation. Whether other E6 functions such as degradation of PDZ domain-containing proteins also contribute to ErbB2 stability remains to be addressed.
Dependence on ErbB2 for tumor formation of HPV16-positive cervical cancer cells Because E6-mediated ErbB2 protein upregulation was found to be essential for transformation of HCK1T-E6E7, we examined whether this is also the case for HPV16-positive cervical cancer cells. ErbB2-shRNA expressing SiHa cells showed reduced ErbB2 protein levels ( Figure 7a ). The exponential growth rate was not affected (Figure 7b) , as in the HCK1T-E6E7 case (Figure 3b ). However, ErbB2 reduced SiHa cells formed fewer colonies in soft agar ( Figure 7c ) and showed greatly reduced tumor formation in nude mice (Figure 7d and e, Po0.0001 for weight of tumors on day 27).
Discussion
Establishment of an in vitro model system for HPV16-mediated multistep carcinogenesis using immortalized normal HCK In this report, we document establishment of an in vitro model system for HPV16-mediated multistep carcinogenesis HPV16 E6 regulates ErbB2 in human cervical keratinocytes M Narisawa-Saito et al using normal HCK, the cells of origin of cervical cancers, with an extended lifespan (HCK1T). Many lines of evidence suggest that integration of HPV DNA and subsequent overexpression of E6 and E7 genes are critical for carcinogenesis in the uterine cervix and with our system, we could show that coexpression of HPV16 E6 and E7 can partially transform cells, enabling them to grow in soft agar. To our knowledge, this is the first report demonstrating that overexpression of HPV16 E6 and E7 proteins themselves support anchorage-independent growth of normal HCK.
CHX
Upregulation of ErbB2 protein levels induced by HPV16 E6 in HCK Overexpression and amplification of ErbB2 in cervical cancer have been demonstrated in various studies (Pinion et al., 1991; Sharma et al., 1999; Hudelist et al., 2005) . In very advanced uterine cervical carcinoma patients, ErbB2 expression is suggested to be predictive of a poor prognosis after radiation therapy (Niibe et al., 2003) . Although these reports all pointed to an importance of ErbB2 in cervical carcinogenesis, not all data have been consistent in this regard (Ngan et al., 2001; Rosty et al., 2004) .
We demonstrated HPV16 E6-mediated upregulation of ErbB2 protein levels when growing beyond confluence in several cell lines. The microarray analysis of subconfluent HCK1T, HCK1T-E6 and HCK1T-E6 mutants defective in p53 inactivation, indicated no deregulation of the ErbB2 gene by E6 or p53 (data not shown). Furthermore, ErbB2 mRNA levels were not altered in the presence of HPV16 E6 (Figure 5a ). Increase in ErbB2 transgene levels in HPV16 E6 and E7 expressing human mammary epithelial cells has been reported (Gewin et al., 2004; Woods Ignatoski et al., 2005) . Thus HPV16 E6 might upregulate ErbB2 expression through translational as well as post-translational modifications and the detailed molecular mechanisms underlying postconfluent regulation of ErbB2 by E6-targeted proteins should be addressed further. The activity of E6 proteins that is most clearly associated with carcinogenesis is degradation of p53 (Scheffner et al., 1990 (Scheffner et al., , 1993 . Our data indicate that it upregulates ErbB2 by increasing its stability, partly through p53 degradation ( Figure 6 ). It is possible that p53 suppresses ErbB2 stability by still unidentified mechanisms under certain circumstances.
HPV16 E6-mediated upregulation of ErbB2 plays an important role in development of cervical cancer In the present study, ErbB2 expression in the presence of HPV16 E6 was increased to about the level in C33A (Figure 4a ), which is reported to be lower than in ErbB2 overexpressing breast cancer cell lines (Beger et al., 2001) . However, our data indicate that E6-mediated upregulation of ErbB2 plays a role in HPV16 E6E7-associated transformation. First, inhibition of ErbB2, either by introduction of ErbB2-shRNA or treatment with its specific inhibitor, abolished the anchorageindependent growth of HCK1T-E6E7 (Figures 2 and 3) .
Furthermore, tumor formation of HPV16-positive SiHa cells was inhibited significantly by introduction of ErbB2-shRNA (Figure 7) indicating that E6-mediated ErbB2 upregulation is important, even in the cancer cell line, SiHa. Therefore, the degree of upregulation of ErbB2 by E6 might be sufficient for development of certain subset of cervical cancer. Although, ErbB2 inhibition with its shRNA reduced the anchorage independent growth abilities of C33A and HeLa cells, it failed to block tumor formation in nude mice (data not shown). Furthermore, HCK1T-E6E7 cells overexpressing wild type ErbB2 or constitutive active mutant (V664E) failed to form tumors (data not shown) although overexpression of HPV16 E6E7 and ErbB2 in primary oral epithelial cells has been reported to induce neoplastic transformation (Al Moustafa et al., 2004) . It is possible that differences in ErbB2 expression levels or cell type are the reasons for the discrepancies. For cervical carcinogenesis, HPV16 E6-mediated ErbB2 upregulation is itself insufficient but might play a role in development of cervical cancer with combinations of additional genetic change(s), such as ras mutations and PIK3CA amplification (Ma et al., 2000) . Detailed analysis of mechanisms of ErbB2 expression and activation profiles during HPV16-mediated cell transformation using primary HCK should hopefully provide us with clues to anti-ErbB2 therapy, for example with trastuzumab (Herceptin), a candidate for cervical cancer control.
Materials and methods
Cell culture and cell lines Normal HCK1s and HCK12s were obtained with written consent from patients who underwent abdominal surgery for a gynecological disease other than cervical cancer. Primary HDKs were purchased from Cell Applications Inc. (San Diego, USA). HCK1s were transduced with the catalytic subunit of hTERT for immortalization (HCK1T) and HCK12s were immortalized with HPV16E6E7 (HCK12-E6E7). They were maintained as previously described (Kiyono et al., 1994) . HCK1T cells have almost normal diploid chromosomes at 120 PD. For the experiments performed here, HCKs before 60 PD were utilized.
Cervical cancer cell lines, SiHa, CaSki, HeLa and C33A were grown in Dulbecco's modified Eagle's medium (DMEM) (Sigma, St Louis, MO, USA) containing 10% FBS.
The specific ErbB2 inhibitor, AG 825, and MG-132 and CHX were from Calbiochem (La Jolla, CA, USA). With assessment of postconfluent growth, AG 825 was added to the media at 2 days after reaching confluent density. For 3-(4,5-dimethyl-2-thiazolyl)-2,5 diphenyl-2H-tetrazolium (MTT) assay (Cell Titer 96 Aqueous One Solution, Promega, Madison, WI, USA), cells were plated at a density of 2000 cells per well in 96-well plates and numbers were estimated.
Vector construction and retroviral transfection Segments of HPV16 E6E7 (16E6E7), a splice donor sitemutant version of E6 (E6SD) (Kiyono et al., 1994) a series of E6 mutants, and hTERT were cloned and recombined into retroviral expression vectors to generate pCLXSN-16E6E7, -16E7, -16E6SD, -16E6 SAT, -16E6 D151, 16E6 L50G and pCLXSH-hTERT, as described previously (Kyo et al., 2003; Takeda et al., 2004) . Construction of the destination vector, pDEST-CL-SI-MSCVpuro, for retroviral expression of shRNA, pCL-SI-MSCVpuro-ErbB2R-shRNA, -HPV16E6-shRNA, -p53-shRNA and -E6AP-shRNA was carried out by a previously described method (Sawada et al., 2004) . The shRNA targeted sequences were as follows: HPV16E6: GTATGGAACAACATTAGAA, E6AP: 5 0 -GAAATCTAGT GAATGATGA-3 0 , p53 (18) and ErbB2 (Yang et al., 2004) as described previously. These entry vectors were recombined with pDEST-CL-SI-MSCVpuro by LR reactions (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Production of recombinant retroviruses was as described (Gewin et al., 2004) . After infection (MOI greater than 1), cells were selected in the presence of 10 mg/ml hygromycin, 1 mg/ml puromycin or 50 mg/ml G418. Cells expressing shRNAs were maintained in puromycin-containing media.
Western analysis
Whole-cell protein extracts were used for Western blottings as described previously (Gewin et al., 2004) with antibodies against ErbB2 (Cell Signaling), b-actin (sc-1616, Santa Cruz, CA, USA), p53 (Oncogene Science, Ab6) and HPV16E6 (Monoclonal antibody (clone 47A) was raised against the N-terminal 16 amino acids) as probes. The LAS3000 CCDImaging System (Fujifilm Co. Ltd., Tokyo, Japan) and Multi Gauge software (Fujifilm) were used for detection and quantification of proteins visualized by Lumi-light plus Western blotting substrate (Roche, Basel, Switzerland).
RNA extraction and Northern Blotting
Total RNA (15 mg) isolated with ISOGEN reagent (Nippon gene Co. Ltd., Tokyo, Japan) was electrophoresed on 1% agarose-formaldehyde gels, transferred on to nylon membranes, and hybridized to 33 P labeled probes. The ErbB2 probe was generated by random primer labeling (Amersham, Piscataway, NJ, USA) a full-length human cDNA of ErbB2. The 36B4 loading control probe was as described previously (Kiyono et al., 1998; Gewin et al., 2004) .
Colony formation in soft agar
Cells were seeded at 5 Â 10 4 cells per 35-mm plate in an appropriate medium (KSFM; Invitrogen, USA, for HCK1Ts) with 0.4% agarose and a 0.7% agarose underlay and HCK1Ts were fed once a week. Colonies over 50 mm in diameter were counted after 4 weeks for HCK1Ts and 10 days for SiHa cells. Five photographs of randomly selected area in each dish were taken at the magnification of Â 40. The numbers of colonies were measured with the COLONY program (Fujifilm).
Tumorigenesis in nude mice
Exponentially growing SiHa cells (1 Â 10 7 ) were trypsinized, resuspended in 75 ml of phosphate-buffered saline and 75 ml of Matrigel (BD Biosciences, San Jose, CA, USA) and subcutaneously injected above the hind legs of female 6 to 7-week old BALB/c nude mice (Clea Japan Inc., Tokyo, Japan). Tumor volumes were measured every other day with calipers. The tumor volume (mm 3 ) was estimated by multiplication of the major axis, the minor axis and the height. Mice were killed after 27 days of monitoring.
Statistical analysis
The data were analysed using the Student's t-test, with Po0.05 considered as significant.
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